Although no criteria may ever be globally applicable, STOPP and START make significant advances. Regional drug availability, economic considerations, and clinical practice patterns impact criteria selection. Research to validate the several newer criteria in various practice settings and to explore the effect of adhering to the guidelines on patient outcomes is warranted. Data from such research will aid practitioners in identifying preferred criteria.

The repair of seven tibiotarsal fractures, three humeral fractures, three tarsometatarsal fractures, two femoral fractures and 13 radial and ulnar fractures with a tubular external fixator system was evaluated prospectively in 10 common pigeons (Columba livia), 11 psittacine birds, six birds of prey and one Bali starling (Leucopsar rothschildii). The fixations included type 1, type 2 and intramedullary tie-in methods, and the fractures healed in all but three cases. A comparison of the weight of different connecting bars showed that the external fixation system and polymethylmethacrylate are the lightest available systems and that there was no clinically relevant difference between them.

PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) is a common cause of unplanned healthcare utilization. The University of Michigan Rogel Cancer Center initiated the chemotherapy remote care monitoring program (CRCMP) to proactively identify patients experiencing CINV and intervene before the need for urgent evaluation. METHODS: High-risk patients for CINV are identified by neurokinin-1 (NK-1) antagonist administration, enrolled in the CRCMP, and received a daily text message survey for 7 days after chemotherapy administration to report symptoms. Responses above a set threshold trigger a message to the team pharmacist for intervention. The primary outcome of 14-day unplanned healthcare use was evaluated before and after CRCMP implementation. RESULTS: In 8 months, 652 patients received an NK-1 antagonist (2,244 cycles) and 387 patients were enrolled in the CRCMP (59%). Text message response rate was 94%. Clinical pharmacists provided 248 interventions in 121 patient episodes meeting threshold criteria. Fourteen-day unplanned healthcare use was decreased in the CRCMP-enrolled NK-1 episodes (6.68% v 4.53%, P = .02). Admissions were numerically lower for those enrolling in CRCMP when only admissions for nausea were considered (0.63% v 0.35%, P = .33). CONCLUSION: The CRCMP allowed for real-time management of patient-reported CINV symptom burden based on patient-reported outcomes (PROs) and an electronic medical record-integrated SMS text questionnaire. Clinical pharmacists were key team members to manage patient symptoms. Enrollment in CRCMP significantly reduced overall unplanned healthcare utilization. Although these changes were numerically small, any reduction in unnecessary care utilizing PROs can contribute to high-value care for patients with cancer.

La propriété qu'ont certains végétaux de coaguler le lait est connue depuis bien longtemps. Ce phénomène est dû à la présence d'une enzyme dont les caractères semblent être pareils à ceux du Zab, enzyme coagulante qui se trouve généralement dans l'estomac des mammifères. Cette enzyme est assez répandue dans le règne végétal et chez les êtres inférieurs. On la trouve dans les. composés, les crucifères, les rubiacés, les renonculacés, les solanées, les plantes carnivores, les algues brunes, les basidiomycètes, etc. Le nombre des travaux connus jusqu'à présent sur ce sujet• peut être considéré comme faible, vu l'importance de ces enzymes. Ainsi nous avons cru intéressant d'entreprendre une 'suite de recherches afin de contribuer à faire mieux connaître ces enzymes et d'étudier en même temps les possibilités de leur emploi dans l'industrie laitière (industrie fromagère, caséinière, etc.). PRÉSURE DU CHARDON Le chardon est une composée très répandue dans les Provinces de Buenos-Airee.tOordoba et sud de Sarrta-Eé ; où elle est considérée comme une plaie de l'agriculture. D'après le botaniste M. L. PARODI, on trouve dans les régions .citées,. les sept espèces de Oynareae suivantes:

No abstract